MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease

Toxicology Letters

Volumn 258, Issue , 2016, Pages 159-167

  Takeuchi Yorimoto, Ayano ^a,b   Yamaura, Yu ^b   Kanki, Masayuki ^b   Ide, Tetsuya ^b   Nakata, Ayumi ^b   Noto, Takahisa ^b,c   Matsumoto, Masahiro ^b  

^a Astellas Pharma Global Development   (Netherlands)

^b ASTELLAS PHARMA INC   (Japan)

^c SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

CDAA; Fibrosis; MiR 21; NASH

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; GELATINASE B; MICRORNA 1; MICRORNA 10B; MICRORNA 142 3P; MICRORNA 155; MICRORNA 15B; MICRORNA 181A; MICRORNA 196B; MICRORNA 203; MICRORNA 21; MICRORNA 214; MICRORNA 27A; MICRORNA 342 3P; MICRORNA 34A; MICRORNA 410; MICRORNA 455; MICRORNA 721; MICRORNA LET 7I; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; CHOLINE; IRON INTAKE; MESSENGER RNA; MICRORNA; MIRN21 MICRORNA, RAT; MMP9 PROTEIN, RAT; TISSUE INHIBITOR OF METALLOPROTEINASE-1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; HISTOPATHOLOGY; LIVER; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; ADVERSE EFFECTS; ANIMAL; BLOOD; CHOLINE DEFICIENCY; COMPLICATION; DIET; DIET THERAPY; DIETARY SUPPLEMENT; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GERMFREE ANIMAL; IMMUNOLOGY; INTOXICATION; IRON INTAKE; IRON OVERLOAD; LIVER CIRRHOSIS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; WISTAR RAT;

ANIMALS; BIOMARKERS; CHOLINE; CHOLINE DEFICIENCY; DIET; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IRON OVERLOAD; IRON, DIETARY; LIVER; LIVER CIRRHOSIS; MATRIX METALLOPROTEINASE 9; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS, WISTAR; RNA, MESSENGER; SPECIFIC PATHOGEN-FREE ORGANISMS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84978909292     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2016.06.012     Document Type: Article

References (32)

1. Abraham, D., Ponticos, M., Nagase, H., Connective tissue remodeling: cross-talk between endothelins and matrix metalloproteinases. Curr. Vasc. Pharmacol. 3 (2005), 369–379.
2. Ambros, V., microRNAs: tiny regulators with great potential. Cell 107 (2001), 823–826.
3. Becker, P.P., Rau, M., Schmitt, J., Malsch, C., Hammer, C., Bantel, H., Müllhaupt, B., Geier, A., Performance of serum microRNAs −122, −192 and −21 as biomarkers in patients with non-alcoholic steatohepatitis. PLoS One, 10, 2015, e0142661.
4. Benyon, R.C., Iredale, J.P., Goddard, S., Winwood, P.J., Arthur, M.J., Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 110 (1996), 821–831.
5. Boye, A., Yang, Y., Hepatic MicroRNA orchestra: a new diagnostic, prognostic and theranostic tool for hepatocarcinogenesis. Mini Rev. Med. Chem. 14 (2014), 837–852.
6. Brunt, E.M., Janney, C.G., Di Bisceglie, A.M., Neuschwander-Tetri, B.A., Bacon, B.R., Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94 (1999), 2467–2474.
7. Cai, P., Gobert, G.N., You, H., Duke, M., McManus, D.P., Circulating miRNAs: potential novel biomarkers for hepatopathology progression and diagnosis of schistosomiasis japonica in two murine models. PLoS Negl. Trop. Dis., 9, 2015, e0003965.
8. Cermelli, S., Ruggieri, A., Marrero, J.A., Ioannou, G.N., Beretta, L., Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One, 6, 2011, e23937.
9. Cheung, O., Puri, P., Eicken, C., Contos, M.J., Mirshahi, F., Maher, J.W., Kellum, J.M., Min, H., Luketic, V.A., Sanyal, A.J., Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 48 (2008), 1810–1820.
10. Duwaerts, C.C., Maher, J.J., Mechanisms of liver injury in non-alcoholic steatohepatitis. Curr. Hepatol. Rep. 13 (2014), 119–129.
11. Dyson, J.K., Anstee, Q.M., McPherson, S., Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 5 (2014), 211–218.
12. Ghiassi-Nejad, Z., Friedman, S.L., Advances in antifibrotic therapy. Expert Rev. Gastroenterol. Hepatol. 2 (2008), 803–816.
13. He, X., Xie, J., Zhang, D., Su, Q., Sai, X., Bai, R., Chen, C., Luo, X., Gao, G., Pan, W., Recombinant adeno-associated virus-mediated inhibition of microRNA-21 protects mice against the lethal schistosome infection by repressing both IL-13 and transforming growth factor beta 1 pathways. Hepatology 61 (2015), 2008–2017.
14. Herbst, H., Wege, T., Milani, S., Pellegrini, G., Orzechowski, H.D., Bechstein, W.O., Neuhaus, P., Gressner, A.M., Schuppan, D., Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am. J. Pathol. 150 (1997), 1647–1659.
15. Iredale, J.P., Benyon, R.C., Arthur, M.J., Ferris, W.F., Alcolado, R., Winwood, P.J., Clark, N., Murphy, G., Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 24 (1996), 176–184.
16. Lendvai, G., Jarmay, K., Karacsony, G., Halasz, T., Kovalszky, I., Baghy, K., Wittmann, T., Schaff, Z., Kiss, A., Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies. World J. Gastroenterol. 20 (2014), 15343–15350.
17. Marquez, R.T., Bandyopadhyay, S., Wendlandt, E.B., Keck, K., Hoffer, B.A., Icardi, M.S., Christensen, R.N., Schmidt, W.N., McCaffrey, A.P., Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab. Invest. 90 (2010), 1727–1736.
18. Matteoni, C.A., Younossi, Z.M., Gramlich, T., Boparai, N., Liu, Y.C., McCullough, A.J., Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999), 1413–1419.
19. Mitchell, P.S., Parkin, R.K., Kroh, E.M., Fritz, B.R., Wyman, S.K., Pogosova-Agadjanyan, E.L., Peterson, A., Noteboom, J., O'Briant, K.C., Allen, A., Lin, D.W., Urban, N., Drescher, C.W., Knudsen, B.S., Stirewalt, D.L., Gentleman, R., Vessella, R.L., Nelson, P.S., Martin, D.B., Tewari, M., Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 10513–10518.
20. Okazaki, I., Noro, T., Tsutsui, N., Yamanouchi, E., Kuroda, H., Nakano, M., Yokomori, H., Inagaki, Y., Fibrogenesis and carcinogenesis in nonalcoholic steatohepatitis (NASH): involvement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase (TIMPs). Cancers (Basel) 6 (2014), 1220–1255.
21. Ries, C., Cytokine functions of TIMP-1. Cell. Mol. Life Sci., 2013.
22. Takeuchi-Yorimoto, A., Noto, T., Yamada, A., Miyamae, Y., Oishi, Y., Matsumoto, M., Persistent fibrosis in the liver of choline-deficient and iron-supplemented L-amino acid-defined diet-induced nonalcoholic steatohepatitis rat due to continuing oxidative stress after choline supplementation. Toxicol. Appl. Pharmacol. 268 (2013), 264–277.
23. Tsochatzis, E.A., Bosch, J., Burroughs, A.K., Liver cirrhosis. Lancet 383 (2014), 1749–1761.
24. Wang, B., Majumder, S., Nuovo, G., Kutay, H., Volinia, S., Patel, T., Schmittgen, T.D., Croce, C., Ghoshal, K., Jacob, S.T., Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 50 (2009), 1152–1161.
25. Wang, J., Gao, Y., Ma, M., Li, M., Zou, D., Yang, J., Zhu, Z., Zhao, X., Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice. Cell Biochem. Biophys. 67 (2013), 537–546.
26. Wang, Y., Liu, Z., Zou, W., Hong, H., Fang, H., Tong, W., Molecular regulation of miRNAs and potential biomarkers in the progression of hepatic steatosis to NASH. Biomark. Med., 2015.
27. Wei, J., Feng, L., Li, Z., Xu, G., Fan, X., MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling. Biomed. Pharmacother. 67 (2013), 387–392.
28. Wu, H., Ng, R., Chen, X., Steer, C.J., Song, G., MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut, 2015, 10.1136/gutjnl-2014-308430 (Epub ahead of print).
29. Xu, G.F., Li, P.T., Wang, X.Y., Jia, X., Tian, D.L., Jiang, L.D., Yang, J.X., Dynamic changes in the expression of matrix metalloproteinases and their inhibitors, TIMPs, during hepatic fibrosis induced by alcohol in rats. World J. Gastroenterol. 10 (2004), 3621–3627.
30. Yoon, J.H., Lee, J.M., Joo, I., Lee, E.S., Sohn, J.Y., Jang, S.K., Lee, K.B., Han, J.K., Choi, B.I., Hepatic fibrosis: prospective comparison of MR elastography and US shear-wave elastography for evaluation. Radiology 273 (2014), 772–782.
31. Zhang, Z., Zha, Y., Hu, W., Huang, Z., Gao, Z., Zang, Y., Chen, J., Dong, L., Zhang, J., The autoregulatory feedback loop of microRNA-21/Programmed cell death protein 4/Activation protein-1 (MiR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development. J. Biol. Chem. 288 (2013), 37082–37093.
32. Zhao, J., Tang, N., Wu, K., Dai, W., Ye, C., Shi, J., Zhang, J., Ning, B., Zeng, X., Lin, Y., MiR-21 simultaneously regulates ERK1 signaling in HSC activation and hepatocyte EMT in hepatic fibrosis. PLoS One, 9, 2014, e108005.